Impact of Data Base Structure in a Successful In Vitro-In Vivo Correlation for Pharmaceutical Products
- 452 Downloads
The in vitro-in vivo correlation (IVIVC) (Food and Drug Administration 1997) aims to predict performances in vivo of a pharmaceutical formulation based on its in vitro characteristics. It is a complex process that (i) incorporates in a gradual and incremental way a large amount of information and (ii) requires information from different properties (formulation, analytical, clinical) and associated dedicated treatments (statistics, modeling, simulation). These results in many studies that are initiated and integrated into the specifications (quality target product profile, QTPP). This latter defines the appropriate experimental designs (quality by design, QbD) (Food and Drug Administration 2011, 2012) whose main objectives are determination (i) of key factors of development and manufacturing (critical process parameters, CPPs) and (ii) of critical points of physicochemical nature relating to active ingredients (API) and critical quality attribute (CQA) which may have implications in terms of efficiency, safety, and inoffensiveness for the patient, due to their non-inclusion. These processes generate a very large amount of data that is necessary to structure. In this context, the storage of information in a database (DB) and the management of this database (database management system, DBMS) become an important issue for the management of projects and IVIVC and more generally for development of new pharmaceutical forms. This article describes the implementation of a prototype object-oriented database (OODB) considered as a tool, which is helpful for decision taking, responding in a structured and consistent way to the issues of project management of IVIVC (including bioequivalence and bioavailability) (Food and Drug Administration 2003) necessary for the implementation of QTPP.
KEY WORDSCPP CQA IVIVC object-oriented database QbD
- 1.Food and Drug Administration. Guidance for industry: extended release oral dosage forms: development, evaluation, and application of in vitro/in vivo correlations US. Washington, DC: Department of Health and Human Services, Food and DrugAdministration Center for Drug Evaluation and Research (CDER); 1997.Google Scholar
- 2.Food and Drug Administration. Quality by design for ANDAs: an example for immediate—release dosage forms. Washington,DC: Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER); 2012.Google Scholar
- 3.Food and Drug Administration. Quality by design for ANDAs: an example for modified dosage forms. Washington, DC: Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER); 2011.Google Scholar
- 4.Food and Drug Administration. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products—general considerations. Washington, DC: Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER); 2003.Google Scholar
- 5.Dunne A. Approaches to developing in vitro – in vitro correlation models. In: Chiliruki DM, Sunkara G, Young D, editors. Drugs and the pharmaceutical sciences, vol 165, pharmaceutical product development in vivo in vitro correlation, Informa. 2007. pp. 47–69.Google Scholar
- 6.Emani J. In vitro–in vivo correlation: from theory to application. J Pharm Pharm Sci. 2009;9:169–89.Google Scholar
- 9.Sirisuth N, Eddington ND. In vivo – in vitro correlation definitions and regulatory guidance. Int J Generic Drugs. 2002. http://www.iagim.org. Accessed 5 Aug 2013.
- 11.Garardin G. Les bases de données. 2èmeth ed. Paris: Eyrolles; 2003.Google Scholar
- 18.Wagner JG. Biopharmaceutics and relevant pharmacokinetics. Hamilton: Drug Intelligence Publications; 1971.Google Scholar